Who should get the pneumococcal vaccine?
Most countries recommend
pneumococcocal vaccine in people at high risk of infection. Some, including
the USA, also recommend it in people aged over 55 with no other risk factors.
In a systematic review, Wiffen et al question both recommendations.
Meta-analysis of data from RCTs found no evidence of benefit in either
group. However, as one of our reviewers points out in an accompanying
commentary, this absence of evidence does not prove absence of benefit.
R Andrew Moore et al (4 October 2000)
BMC Family Practice 2000 1:1
A ‘pan-muscle’ promoter?
Understanding of the detailed expression
profiles of promoter/enhancer elements is a requirement for gene therapy. Hallauer and Hastings analyse expression
of the ‘universal’ CMV IE1 promoter in skeletal muscle, and find that expression is not fiber-type specific.
CMV IE1 thus appears to be the first promoter to be identified that drives expression in both fast and slow muscle fibers.
Patricia L Hallauer and Kenneth E M Hastings (4 October 2000)
BMC Genetics 2000 1:1
Rejection after renal transplantation is more likely if the patient is diabetic.
Thomas et al hypothesise that this is due to peri-operative hyperglycaemia and studied whether a raised blood sugar alone could influence rejection,
even in non-diabetic patients: 71% of hyperglycaemic patients develop rejection, compared to only 42% of non-hyperglycaemic patients.
This has implications for peri-operative blood sugar control.
Merlin C Thomas et al (4 October 2000)
BMC Nephrology 2000 1:1